IDH1 and astrocytoma (excluding glioblastoma): Patients with infratentorial IDH mutant astrocytomas have significantly better clinical outcomes compared to those with diffuse midline gliomas harboring the H3K27M mutation, but significantly worse outcomes than patients with supratentorial IDH mutant astrocytomas (Banan et al., 2020).